New study provides insights into COVID-19 vaccine uptake among children and young people
COVID-19 vaccine uptake among children and young people was low across all four UK nations according to pioneering new research
SWANSEA UNIVERSITY
COVID-19 vaccine uptake among children and young people was low across all four UK nations, compared to other age groups, according to the first research study to look at data from all four UK nations.
It also revealed that uptake further reduced for second and booster vaccinations.
Uptake of COVID-19 vaccination was associated with age and sex of the child and young person, as well as number of people and vaccination status of the household.
The research, led by Professor Rhiannon Owen at Swansea University and Professor Sir Aziz Sheikh at the University of Edinburgh, linked health and administrative data to explore COVID-19 vaccine uptake in over 3.4 million children and young people aged between 5 and 17 in the UK.
The research, published in Nature Communications, was a collaboration between Swansea University, the University of Oxford, Queen's University Belfast, the University of Edinburgh, and Strathclyde University.
The study looked at anonymised data between August 4, 2021, and May 31, 2022. It explored the factors influencing vaccine uptake among children and young people, including sex, age, and household factors, while accounting for delays in vaccine uptake due to infection.
The study used multi-state modelling and meta-analysis techniques to identify key demographic variables influencing vaccine uptake among children and young people on a national scale.
The study showed that across the UK nations 35 per cent of children and young people received the first vaccine, 21 per cent received the second, and 2 per cent received the booster dose. During the study period 13 per cent tested positive for COVID-19 and 133 died of all-causes.
Children and young people aged five to 11 years old were 90 per cent less likely to receive their first COVID-19 vaccine, and 12 to 15-year-olds were 42 per cent less likely compared to 16 to 17-year-olds.
The researchers revealed that children and young people in unvaccinated households were 81 per cent less likely to receive their first COVID-19 vaccine compared to children and young people from households with at least one vaccinated adult.
Males were 7 per cent less likely to receive their first vaccine compared to females, and children and young people residing in single adult households were 11 per cent less likely to receive their first vaccine compared to children living in households with two people.
First author Sarah Aldridge, researcher and data scientist at Population Data Science at Swansea, said: “Our research emphasises the critical role of prioritising COVID vaccination efforts for children and young people. The data highlights the necessity for targeted interventions to address specific risk factors, ensuring widespread protection and mitigating potential impacts on this age group.
“To prepare for possible future pandemics, understanding and addressing vaccination differences among vulnerable populations are critical to effective public health strategies."
JOURNAL
Nature Communications
METHOD OF RESEARCH
Data/statistical analysis
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Uptake of COVID-19 vaccinations amongst 3,433,483 children and young people: meta-analysis of UK prospective cohorts
ARTICLE PUBLICATION DATE
22-Mar-2024
COI STATEMENT
AS has served on a number of UK and Scottish government COVID-19 advisory bodies. CR has served on a number of UK and Scottish government COVID-19 advisory bodies—SPI-M, MHRA Covid Vaccines Benefit and Risk Group, Scottish Government Covid Advisory Group and Chief Nursing Officer Nosocomial Advisory Group. DTB has served on a number of UK and Northern Ireland government COVID-19 advisory bodies. All other authors report no competing interests. RAL was a member of the Welsh Government COVID-19 Technical Advisory Group. RKO is a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, member of the NICE Decision Support Unit (DSU), and associate member of the NICE Technical Support Unit (TSU). RKO has served as a paid consultant to the pharmaceutical industry, providing unrelated methodological advice generally. She reports teaching fees from the Association of British Pharmaceutical Industry (ABPI) and the University of Bristol. SdeL has received grants through his University for vaccine related research from AstraZeneca, GSK, Moderna, MSD, Sanofi and Seqirus. He has also been a member of advisory boards for AstraZeneca, GSK, Sanofi and Seqirus, with any funding paid to his University. The remaining authors have nothing to declare.
Can taking antibiotics combat the gut bacteria that contribute to the pathogenesis of COVID-19?
New research indicates that antibiotics can effectively target bacteria in the gut that harbor the virus that causes COVID-19 and produce toxin-like peptides that contribute to COVID-19-related symptoms. In the study, which involved 211 participants and was published in the Journal of Medical Virology, individuals who received early antibiotic treatment after having COVID-19 recovered more quickly than those who did not receive antibiotics.
The authors had already evaluated the efficacy of certain antibiotics in SARS-CoV-2-infected bacterial cultures in vitro, and this new study demonstrates promising results with the use of the combination of 2 antibiotics (amoxicillin and rifaximin) within the first 3 days.
Furthermore, a significant number of patients who received antibiotics within the first 3 days and for a duration of 7 days during the acute phase of COVID-19 did not develop long COVID.
"Our findings suggest that antibiotics should be considered in acute infection and Long COVID. The study also lays the foundation for additional vaccine strategies," said co–corresponding author Marina Piscopo, PhD, of the University of Naples Federico, in Italy.
URL upon publication: https://onlinelibrary.wiley.com/doi/10.1002/jmv.29507
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Journal of Medical Virology is a clinical virology journal publishing original scientific papers on fundamental and applied research concerning viruses affecting humans. We welcome reports describing the characterization, diagnosis, epidemiology, immunology and pathogenesis of human viral infections and diseases. Basic studies on virus morphology, genetics, replication and host-cell interactions are also accepted.
About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world's most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.
JOURNAL
Journal of Medical Virology
ARTICLE TITLE
A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID-19 patients
ARTICLE PUBLICATION DATE
20-Mar-2024
No comments:
Post a Comment